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Abstract
Despite considerable success of genome wide association (GWA) studies in identifying causal variants for many human
diseases, their success in unraveling the genetic basis to complex diseases has been more mitigated. Pathogen population
structure may impact upon the infectious phenotype, especially with the intense short-term selective pressure that drug
treatment exerts on pathogens. Rigorous analysis that accounts for repeated measures and disentangles the influence of
genetic and environmental factors must be performed. Attempts should be made to consider whether pathogen diversity
will impact upon host genetic responses to infection. We analyzed the heritability of two Plasmodium falciparum
phenotypes, the number of clinical malaria episodes (PFA) and the proportion of these episodes positive for gametocytes
(Pfgam), in a family-based cohort followed for 19 years, during which time there were four successive drug treatment
regimes, with documented appearance of drug resistance. Repeated measures and variance components analyses were
performed with fixed environmental, additive genetic, intra-individual and maternal effects for each drug period. Whilst
there was a significant additive genetic effect underlying PFA during the first drug period of study, this was lost in
subsequent periods. There was no additive genetic effect for Pfgam. The intra-individual effect increased significantly in the
chloroquine period. The loss of an additive genetic effect following novel drug treatment may result in significant loss of
power to detect genes in a GWA study. Prior genetic analysis must be a pre-requisite for more detailed GWA studies. The
temporal changes in the individual genetic and the intra-individual estimates are consistent with those expected if there
were specific host-parasite interactions. The complex basis to the human response to malaria parasite infection likely
includes dominance/epistatic genetic effects encompassed within the intra-individual variance component. Evaluating their
role in influencing the outcome of infection through host genotype by parasite genotype interactions warrants research
effort.
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Introduction
The genomics era has heralded a plethora of Genome Wide
Association (GWA) studies that have successfully identified genetic
determinants of many medical disorders [1–4]. Heritability
analyses provide an indication of the genetic contribution
underlying a specified phenotype. Whereas in the case of
monogenic diseases genetic determinants in GWA studies account
for the estimated heritability, there is considerable missing
heritability in more complex diseases [5]. This had led to an
intense debate of the potential causes for this, citing amongst
others the potentially important roles of epistasis, gene-environ-
mental interaction and the confounding effect of population
specific genetic architecture [6]. In addition to genetic explana-
tions, one potential source contributing to the missing heritability
concerns the phenotype; poorly resolved phenotypes lower the
power to detect genetic variants [7].
The application of GWA studies to infectious diseases has only
more recently developed [8–10], but is likely to become
increasingly implemented [11]. Infectious disease phenotypes
are, however, composite phenotypes reflecting both the human
and pathogen genetics and their interactions. Thus, the phenotype
‘‘problem’’ is likely to be much greater than in non-infectious
diseases. Over the long-term, host-pathogen co-evolution will
maintain genetic variation if the additive genetic value of a host
genotype changes when parasites evolve in response to the
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selection induced by the host [12]. This, thus, may be apparent in
the local genetic architecture of the human genetics determining
specific traits, where populations have undergone widely different
exposure to the pathogen. In addition, despite the current efforts
to untangle the genetic basis to complex diseases [13], no attention
has been paid to the impact of radical short-term changes in the
pathogen population genetic structure, such as those induced by
drug pressure, on the human genetic contribution to infection
phenotypes.
In recent years, particular attention has been paid to addressing
the human genetic susceptibility and resistance to Plasmodium
falciparum malaria [14–16]. Sickle cell trait has long been
recognized as having a protective effect against severe disease
[17,18] and this provided a positive control for the first GWA
study of severe malaria [19]. Following this success and in the
knowledge that the human genetic response to malaria parasite
infection is complex and polygenic [20], it is now widely admitted
that well-conducted epidemiological studies that take into account
confounding environment factors are required [21]. In general,
the requisite large sample size for GWA studies necessarily means
combining participants from many sites. Whilst among-site
variation in human population sub-structure and in the intensity
of transmission can in principle be taken into account, such
confounding variation may have more subtle effects. Variation in
the intensity of transmission, for example, not only has discernable
effects on the development of immunity, it also influences parasite
genetic diversity [22].
To date genetic analyses have implicitly assumed that any
variation brought about by parasite diversity will only have a
minor impact, especially with very broad binary phenotypes such
as severe versus mild malaria. This has been to some extent
confirmed in animal models, but significant host-by-parasite
interactions have been observed [23]. In contrast to such extreme
binary disease phenotypes, there has been increasing interest in
quantitative phenotypes that describe the outcome of infection
[16,24–27]. Such phenotypes focus on the actual biology of the
parasite within the human host, rather than the extreme disease
phenotype, but may be more affected by changes in parasite
diversity. Parasite genetic variation in growth rate, transmissibility
and other biological phenotypes is well recognized [28] and thus
quantitative malaria phenotypes may be influenced strongly by
parasite genetics. Indeed, it was recently demonstrated that there
was a parasite genetic contribution to time to clearance following
treatment [29]. Transmission intensity influences the number of
different parasite clones within an infection, which itself can
impact on quantitative phenotypes [30]. Moreover, malaria
parasites exhibit extensive phenotypic plasticity and quantifiable
parasite phenotypes are affected by the immunological and
hematological state of the host [31]. Finally, parasite populations
evolve over time, especially in the face of persistent drug pressure
and there has been recent suggestion that drug resistance is linked
to or will select for virulence of the parasite [32,33]. All such
sources of variation in the parasite population may significantly
alter the observed outcome of infection and thus cloud the signal
in the genetic analyses.
Here we address the extent to which malaria phenotypes in a
longitudinal family-based epidemiological study are influenced by
the changes in anti-malarial drug treatment and in transmission
intensity from 1990 to 2008. We estimate the heritability of two P.
falciparum-related phenotypes: the number of clinical malaria
episodes (PFA) [16] and the proportion of infections carrying
gametocytes (parasite stages that can infect mosquitoes) (Pfgam)
[27,34]. Heritability is an important parameter that determines
statistical power in gene-mapping studies that use pedigree
information. A large heritability implies a strong correlation
between phenotype and genotype, so that loci with an effect on the
phenotype can be more easily detected [35]. These two
phenotypes were chosen to be representative of different types of
phenotype: PFA will be strongly influenced by variation in
transmission intensity, whereas Pfgam will more strongly reflect
the host-parasite interaction. In addition to calculating the
heritability, we estimate the shared environment (here house)
and intra-individual (also known as ‘‘permanent environment’’)
effects, including maternal effects.
Materials and Methods
Ethics statement
The project protocol and objectives were carefully explained to
the assembled village population and informed consent was
individually obtained from all subjects either by signature or by
thumbprint on a voluntary consent form written in both French
and in Wolof, the local language. Consent was obtained in the
presence of the school director, an independent witness. For very
young children, parents or designated tutors signed on their
behalf. The protocol was approved by the Ethical Committee of
the Institut Pasteur de Dakar and the Ministère de la Santé et de la
Prévention of Senegal. An agreement between Institut Pasteur de
Dakar, Institut de Recherche pour le Développement and the
Ministère de la Santé et de la Prévention of Senegal defines all
research activities in the study cohorts. Each year, the project was
re-examined by the Conseil de Perfectionnement of the Institut
Pasteur de Dakar and the assembled village population; informed
consent was individually renewed from all subjects.
Study site and study population
The study was conducted in the malaria research project carried
out since 1990 in a family-based cohort in Senegal, which has
perennial holoendemic transmission (high force of infection). This
site is managed by a tripartite agreement between the Institut
Pasteur de Dakar, the Institut de Recherche pour le Développe-
ment and the Ministère de la Santé et de la Prévention of Senegal.
A field research station with a dispensary run by nurses was
constructed for the program and the health care is free-of-charge
for the volunteers. All participants were asked to come to a study
clinic for all their healthcare needs. Every person satisfying
adhesion conditions could become a volunteer and every volunteer
could leave the study at any time, therefore forming a dynamic
open cohort. Further details of the study sites and adhesion criteria
are previously described [36,37].
The family structure (pedigree) was available after a demo-
graphic census performed for every volunteer at his adhesion in
the project. A verbal interview of mothers or key representatives of
the household was used to obtain information on genetic
relationships between studied individuals, their children, their
parents, and to identify genetic links among the population. The
total pedigree comprised 828 individuals, including absent or dead
relatives, composed of 206 nuclear families (father – mother
couples with at least one child) with an average of 3.6 children
each. In addition, previous typing with microsatellites has enabled
the construction of a pedigree based on Identity-by-Descent (IBD)
using MERLIN [16,38].
Data collection - P. falciparum malaria phenotypes
The parasite phenotypes analyzed were: (i) the number of
P. falciparum clinical episodes per trimester (PFA) and (ii) the
proportion of clinical episodes that were positive for gametocytes,
parasite stages transmissible to mosquitoes (Pfgam). A malaria
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episode is defined as a clinical presentation with measured fever
(axillary temperature .37.5uC) or fever-related symptoms (head-
ache, vomiting, subjective sensation of fever) and with a blood
smear positive for P. falciparum at a parasite/leukocyte ratio higher
than the age-dependent pyrogenic threshold previously defined by
Rogier et al. [39]. For PFA, we first excluded any observations of
each trimester for which the individual concerned was not present
for at least 30 days ( = 1/3 of the trimester). Individuals satisfying
presence conditions without any P. falciparum clinical episode in a
trimester were classified as PFA = 0; individuals satisfying presence
conditions with 1 or more malaria clinical episodes in a trimester
correspond to person-trimester with PFA = {1, 2, 3, 4, or 5}.
Repeated clinical presentations within 15 consecutive days were
not considered to be independent and were excluded from the
analyses, unless there was a parasite negative blood smear between
two clinical episodes. In all cases parasite positivity was established
as follows. Thick and thin blood films were prepared and stained
by 3% Giemsa stain. Blood films were examined under an oil
immersion objective at 61000 magnification by the trained
laboratory technicians and 200 thick film fields were examined
to count the number of asexual and gametocyte parasite stages.
The proportion of clinical episodes carrying gametocytes excluded
any repeated clinical presentations within 15 days of previous
treatment.
The following covariates were considered: sex, house, season (4
categories: Jul–Sep; Oct–Dec; Jan–Mar; Apr–Jun) nested within
year, year (5 categories: 1990 to 1994 for quinine period, 5
categories: 1995 to 1999 for 1st chloroquine period, 4 categories:
2000 to 2003 to the 2nd chloroquine period, 3 categories: 2004 to
2006 for fansidar period, 3 categories: 2006 to 2008 for ACT
period) and logarithm of number of days present in each trimester.
For Pfgam, we additionally considered the presence of other
Plasmodium spp. parasites (Plasmodium ovale and Plasmodium malariae;
2 categories: yes/no) and time since last treatment. For Pfgam, age
was found to be best described as a continuous variable in each
drug period. By contrast, age classes ,5 years, [5–15[, [15–35[
and $35 years best described the effect of age on PFA. Only
individuals for whom there was pedigree information were
included in the analysis.
Data analyses
From 1990 to 2008, four different drug regimens were
implemented: Quinine from 1990 to 1994, Chloroquine from 1995
to 2003, Fansidar from 2004 to mid-2006 and Artemisinin-based
combination therapy (ACT) from mid-2006 to 2008. The chloroquine
drug period was divided into before (CQ1) and after (CQ2) 1999.
This was done both to reduce the chloroquine period data set size
and to examine the chloroquine periods prior to and during the
observed emergence of parasite resistance to this drug [40]. The
statistical analyses were performed independently for each of the
five drug treatment periods.
We implemented Generalized Linear Mixed Models (GLMM)
using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA) procedures
GLIMMIX, MIXED and INBREED [41–43]. GLMM allows
fitting of mixed models with correlated random effects, such as
those due to genetic relationships. Random effects are assumed to
be normally distributed, and conditional on these random effects,
the exogenous variable had (i) a Poisson distribution when the
studied phenotype was number of P. falciparum clinical episodes per
trimester (PFA) or (ii) a Binomial distribution when the studied
phenotype was the proportion of clinical episodes that were
positive for gametocytes (Pfgam). Genetic covariance, or relation-
ship among all pairs of individuals in the study and among their
parents or more distant ancestors, were stored in a squared matrix,
the Pedigree-based genetic relatedness matrix, of dimension K6K
where K is the total number of individuals in the pedigree
including those with missing phenotypes. Genetic covariance
between two individuals was computed using the pedigree
information as described below:
For A and B, a given pair in a pedigree, the genetic covariance
is computed as r(A,B) = 26 coancestry(A,B) where the coancestry
between A and B is calculated using the method presented in
Falconer and Mackay (1996) [44]: coancestry(A,B) =Sp(1/2)
n(p)6(1 +
I Common Ancestor) where p is the number of paths in the pedigree
linking A and B, n(p) the number of individuals (including A and B)
for each path p and IX is the inbreeding coefficient of an individual
X, which is equal to the coancestry between the two parents of X. IX
is set to 0 if X is a founder. This matrix was built using INBREED
procedure of SAS and then integrated into the models [42].
The objective of the model used for the analysis was to estimate
and separate different sources of variation underlying the total
variation observed for the phenotype: the relative contributions of
human genetics (additive genetic variance), intra-individual vari-
ance, maternal effects, house effects and unexplained residual
variation. The repeated measurements design allows us to separate
additive genetic variance from intra-individual variance. The
occurrence of related individuals living in different houses allows
separation of additive genetic variance from that due to shared
household. Therefore, the random part of the mixed models
included (i) the house identification variable as random effect
assuming independence between houses to capture variance due to
houses, (ii) the individual identification variable twice: a first time to
capture the additive genetic variance by assuming non-indepen-
dence between individuals and using the subpart of the Pedigree-
based genetic relatedness matrix concerning individuals for which
the phenotype was observed as covariance matrix between all pairs
and a second time to capture other individual variances (e.g. intra-
individual effects) assuming independence between individuals and
(iii) the mother identification variable to capture maternal effects,
assuming non-independence between mothers and offspring, using
the subpart of the Pedigree-based genetic relatedness matrix
concerning mothers of individuals for which the phenotype was
observed. The unexplained residual variation was then deduced.
PFA was analyzed using a Poisson regression model, which
explicitly takes into account the non-negative integer-valued aspect
of the dependent count variable. Therefore a GLMM with a
Poisson distribution was fitted using SAS proc GLIMMIX and log
as the link function between E(PFA | covariates) and a predictor that
is linear. Initially a maximal model with all covariates was fitted
and a minimal adequate model including only significant
covariates was obtained. The effect of each covariate on the
outcome variable was estimated taking into account both
inbreeding, via the genetic relatedness matrix integrated in the
SAS Proc GLIMMIX using the LDATA option, and repeated
measures, as well as house effects.












* N 0 ;
ANs
2
g 0 0 0 0
0 AMs
2




0 0 0 IH s
2
c 0











where g is the additive genetic effect, m is the maternal effect, b is
the intra-individual effect, c is the house effect and e is a random
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represents the matrix of additive genetic relationships between
individuals, with dimension N6N, AM represents the matrix of
additive genetic relationships of mothers to offspring, with
dimension M6M, IN is an identity matrix with dimension N6N,
IH is an identity matrix with dimension H6H, and In is an identity
matrix with dimension n6n; and n =Sini where ni is the number of
measure for individual i, N is the number of individuals for which
the phenotype was observed and M the number of their mothers.
The heritability is defined by sg
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For each variance component, an estimate was also generated
for each individual contributing to the overall component. Thus,
for the additive genetic and intra-individual effects, an estimate
was established for each person. Similarly for house and maternal
effects, estimates were established for each house and mother.
Pfgam was analyzed by fitting a GLMM with a Binomial
distribution, using SAS proc GLIMMIX [41]. The distribution of
random effects and corresponding indices were defined as for PFA
in the first analysis.
Results
Data description and epidemiological analyses of key
environmental factors
The first composite phenotype considered was the number of P.
falciparum clinical episodes per person per trimester (PFA). Over the
19-year study period, 713 individuals were present from between
one and 75 complete trimesters generating 22,169 person-
trimesters of presence. There were a total of 5,680 clinical P.
falciparum episodes. The maximum number of PFA per person-
trimester was five and the median was one. 485 individuals had at
least one PFA positive trimester during the study period. The
maximum number of clinical episodes per person per drug period
was 40 and the median was two. Table 1 summarizes the data by
drug period and additionally gives the mean relatedness (by IBD)
of the individuals present in each period. The number of clinical
episodes decreased with age (P,0.0001) and this decrease was
most accurately described by 4 groups (,5 years, 5–14 years, 15–
34 years and .35 years old). Year and season also had a consistent
influence on the number of clinical episodes (P,0.0001). The
incidence rate of clinical episodes per trimester decreased
significantly following the introduction of Fansidar; this change
in the incidence rate is most evident in the most susceptible age
group (,5 years of age) (Figure 1).
The second composite phenotype considered was the number of
P. falciparum clinical episodes that were positive for gametocytes,
the parasite stage transmissible to mosquitoes. The prevalence of
gametocytes at clinical presentation increased from 37% in the
quinine period to 48% in both the chloroquine periods before
decreasing to 17% and 12% in the Fansidar and ACT periods
respectively (Table 1). The percentage of individuals ever
gametocyte positive when having a clinical P. falciparum episode
likewise increased from 50% in the quinine period to 75% in the
second chloroquine period before decreasing to 37% and 25% in
the Fansidar and ACT periods respectively. Age, as a continuous
variable, was found to negatively associate with gametocyte
presence during the quinine (P = 0.02), and the two chloroquine
periods (P,0.001). Yearly variation had a significant impact in all
periods except ACT. An increasing number of days of individual
presence increased gametocyte carriage in the CQ1 period
(P = 0.02) and increasing time since last drug treatment increased
gametocyte carriage in the Fansidar period (P = 0.02).
Heritability analyses – (i) number of P. falciparum clinical
episodes per trimester
A. Additive genetic, intra-individual, maternal and house
variance components. The narrow sense heritability of PFA
was estimated by drug period. During the quinine period there
was significant heritability, estimated at 46%, but which decreased
and became non-significant in the subsequent drug treatment
periods (Figure 2 and Table 2). Conversely, the intra-individual
effect increased significantly following the quinine period,
accounting for over 50% of the observed variance in PFA.
There was no house effect during any period (Figure 2 and
Table 2).
The intra-individual effect includes, amongst other parameters,
any maternal contribution, whether genetic or environmental. In
the case of malaria parasite infection, for example, maternal
antibodies protect the newborn during the first few months of life
and thus the mother transfers her acquired immunity. In addition,
infection during pregnancy can lead to low birth weight with
consequent effects on health of the newborn and potentially later
in life [45]. Thus, as classically performed in heritability analyses,
we consequently evaluated the contribution of a maternal effect in
addition to the additive genetic and intra-individual effects. There
was no maternal effect during any drug period.
B. Additive genetic and intra-individual estimates for
individuals. Estimates for the additive genetic variance strongly
correlated for all the three drug periods for which the total additive
genetic variance was not zero (i.e. thus for which there were non-
zero genetic estimates per individual). There were only individual
significant estimates for the additive genetic effect during the
quinine period. Nineteen individuals had significant estimates
during the quinine period; fourteen of these were present during
more than one drug period but none had significant estimates
subsequent to the quinine period. By contrast, five of them had
significant estimates for the intra-individual effect in periods
subsequent to the quinine period. Overall, individual estimates of
genetic effects were highly correlated with intra-individual effects
by drug period when non-zero (i.e. for quinine, CQ1 and CQ2
periods, Table 3) (r = 0.73, 0.71 and 0.65 respectively).
By definition, major components of the intra-individual
variance are features that are particular to each individual.
Pertinent to malaria parasite infection would be heterogeneity in
exposure to mosquitoes but that which is independent of any
detectable household spatial effect; i.e. specific individual behav-
iors that lead to differential exposure to mosquitoes. We examined
how the intra-individual estimates for each individual were
correlated over the drug periods. Estimates always correlated in
the drug period that followed, but decreasingly so in subsequent
drug periods (Table 3). Estimation of the individual contributions
to the overall intra-individual effects revealed that 54, 47, 91 and
76 individuals had significant estimates in the CQ1, CQ2,
Fansidar and ACT periods respectively. There were no individuals
with significant estimates during the quinine period. The majority
of these individuals (129 of 191) had a significant estimate in only
one drug period. Fifteen and 47 individuals had significant
estimates in three and two drug periods respectively.
Of the 210 individuals present throughout the 19 year period,
69 had significant intra-individual estimates: fifty individuals in
only one treatment period and the remainder in two (n = 15) or
three (n = 4) different periods. Figure 3 displays a comparative
scatter plot of intra-individual estimates in all drug periods. For
simplicity, only the 50 individuals with significant estimates during
a single drug period are highlighted: individuals with a significant
estimate in a specific period are denoted as red stars (CQ1), green
squares (CQ2), blue triangles (Fansidar) and yellow circles (ACT)
Longitudinal Study of Malaria Heritability
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in every graph. In the vertical quinine box column, all points
cluster around zero with respect to the x-axis – there is no intra-
individual effect in the quinine period. This negligible intra-
individual variance component in the quinine period and the
subsequent increase in the following periods can be clearly seen in
Figure 3: the data points are increasingly spread out along the x-
axis from the quinine column through the CQ1, CQ2 and
Fansidar columns. The extreme significant values in the CQ1 (red
stars), CQ2 (green squares), Fansidar (blue triangles) and ACT
(yellow circles) periods clearly separate from the rest in their
respective drug periods: thus for example the individuals
represented by yellow circles have much larger values than the
others in the ACT Y-axis row, whereas these same individuals do
not differ from the rest in the CQ1, CQ2 and Fansidar Y-axis
rows. This shows in detail how individuals with much higher or
lower numbers of P. falciparum episodes (very positive or very
negative values) have so in only single drug periods. Interestingly,
the degree to which the significant points separate from the rest
appears to increase with time (i.e. from CQ1 through ACT); the
blue triangles (Fansidar) and yellow circles (ACT) are more clearly
separated from the rest in their respective Y-axis rows. This
increase in the intra-individual variance component as displayed
though individual estimates over time is reflected in the
summarized intra-individual variance component in Table 2. This
Table 1. Data summary for analyses of the number of P. falciparum clinical episodes per person per trimester (PFA) and the

















Quinine 4080 338 0.0082 1454 234 1–40 37.2 117 1–16
CQ1 5469 405 0.0080 1950 245 1–38 47.1 151 1–26
CQ2 4800 423 0.0081 1481 205 1–38 48.6 155 1–28
Fansidar 3753 417 0.0084 466 148 1–11 17.1 55 1–5
ACT 4067 487 0.0083 329 135 1–10 12.2 34 1–3
Shown are the total number of person-trimesters per drug treatment period in which the number of P. falciparum clinical episodes occurred, the number of individuals
present, their overall genetic relatedness (IBD), the number having a clinical episode, the range in the number of episodes per person, the percentage of these episodes
that were positive for gametocytes, the number of individuals ever carrying gametocytes during a clinical episode and the range in the number of times individuals
carried gametocytes.
doi:10.1371/journal.pone.0026364.t001
Figure 1. The incidence rate (mean and SEM) of clinical P. falciparum episodes per person-trimester (PFA) according to age classes
(from left to right on the X-axis) ,5 years, [5–15], [15–35] and $35 years that best describe the effect of age on PFA.
doi:10.1371/journal.pone.0026364.g001
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shows that as the overall incidence rate drops, there is a growing
gap between certain individuals having a high numbers of episodes
and the rest. Comparing across drug periods, not only do period-
specific significant individual estimates become non-significant in
subsequent periods, they seemingly take on increasingly opposed
values. This is most evident for CQ1, where the significant
estimates for this period, denoted by red stars, decrease in value
during the CQ2 and Fansidar periods (Figure 3, horizontal row
‘‘ACT’’). Similarly for CQ2, significant estimates (green squares)
became less than zero in the Fansidar and ACT periods. This
suggests that individuals with previously very high numbers of
clinical episodes have increasingly fewer numbers of episodes than
the rest. One explanation for this would simply be the acquisition
of clinical immunity due to repeated exposure to the parasite.
As can be seen in Figure 1, age is a reasonable proxy of the
acquisition of immunity and both age and time spent within the
site impact upon incidence rate. However, no single factor was
found to be shared by individuals with significant intra-individual
estimates. I.e. Age, gender and time spent within the village since
inception of the study or during the six months prior to the episode
were not significant variables determining the intra-individual
estimate.
In the knowledge that resistance to chloroquine and then
Fansidar emerged during the respective drug treatment periods, a
potentially confounding factor would clearly be repetitive
presentation of a single infection because of treatment failure.
To evaluate whether the observed increases in the intra-individual
variance was a result of drug treatment failure, we examined
whether individuals with significant individual intra-individual
estimates had a shorter time since previous treatment in the
quinine and chloroquine periods, when incidence rate remained
high and stable. Although the time since previous treatment for
those individuals having significant intra-individual estimates at
any time was shorter than for those never having significant
estimates (P,0.001), drug period per se had no effect (P = 0.31).
Thus, there was no difference in time between infections in the
quinine and 2 chloroquine periods, suggesting that treatment
failure was not causing this significant increase in the intra-
individual variance component.
Figure 2. Proportion of variance in the number of clinical P. falciparum episodes per trimester explained by additive genetic (solid
line), intra-individual (dotted line, squares) and house (thin dotted line, triangles) effects.
doi:10.1371/journal.pone.0026364.g002
Table 2. Variance component analyses of the number of P.
falciparum clinical episodes (PFA) according to drug period.






Genetic 0.941 0.384 2.450 0.014 0.189 1.693
Intra 0.391 0.247 1.580 0.057 0.152 2.343
House 0.030 0.106 0.280 0.390 0.003 8546
residual 0.692 0.016 43.410 ,.0001 0.662 0.725
Chloroquine 1
Genetic 0.257 0.205 1.250 0.211 20.145 0.658
Intra 1.106 0.209 5.300 ,.0001 0.789 1.664
House 0.039 0.059 0.670 0.252 0.007 85.995
residual 0.603 0.012 50.300 ,.0001 0.580 0.627
Chloroquine 2
Genetic 0.281 0.242 1.160 0.246 20.193 0.756
Intra 1.230 0.229 5.370 ,.0001 0.880 1.838
House 0.101 0.109 0.930 0.177 0.026 6.787
residual 0.493 0.011 46.870 ,.0001 0.473 0.514
Fansidar
Genetic 0.000 - - - - -
Intra 1.797 0.214 8.380 ,.0001 1.441 2.304
House 0.036 0.059 0.610 0.272 0.006 392.83
residual 0.395 0.010 41.290 ,.0001 0.377 0.415
ACT
Genetic 0.000 - - - - -
Intra 1.759 0.208 8.450 ,.0001 1.413 2.250
House 0.125 0.096 1.300 0.098 0.042 1.390
residual 0.357 0.008 43.240 ,.0001 0.341 0.374
Genetic – additive genetic effect; Intra – Intra-individual effect; House – House
effect.
doi:10.1371/journal.pone.0026364.t002
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Table 3. Correlation of individual estimates of (i) the intra-individual and (ii) additive genetic effects underlying the variation in the
number of P. falciparum clinical episodes according to drug period.
PFA
(i) Intra Quinine CQ1 CQ2 Fansidar ACT
Quinine 0.49*** 0.04 20.01 0.04
CQ1 0.30*** 0.002 0.04
CQ2 0.29*** 0.18*
Fansidar 0.16*







Figure 3. Comparative scatter plot of the Intra-individual estimates per individual per drug period for those individuals present
throughout the study period. Individuals with significant intra-individual estimates at any period are shown in color: red stars (significant in CQ1),
green squares (significant in CQ2), blue triangles (significant in Fansidar) and yellow circles (significant in ACT).
doi:10.1371/journal.pone.0026364.g003
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Heritability analyses – (ii) prevalence of gametocytes
during clinical P. falciparum episodes
A. Additive genetic, intra-individual, maternal and house
variance components. Heritability for the prevalence of
gametocytes during clinical presentation only approached
significance during the Fansidar period (P = 0.057) (Table 4,
Figure 4). By contrast, the intra-individual effect increased
significantly during the chloroquine periods, before becoming
non-significant in the Fansidar and ACT periods. There were no
house or maternal effects.
B. Additive genetic and intra-individual estimates for
individuals. Correlation between estimates for the individual
intra-individual and genetic effects revealed a similar pattern to
PFA: there was significant correlation between estimates in
consecutive drug periods, both with respect to estimates of
individual intra-individual and additive genetic effects, but no
correlation between more distantly related periods (Table 5).
Moreover, individual estimates of the genetic and intra-individual
effects by drug period were again highly correlated when non-zero
(i.e. for Quinine, CQ1, and ACT periods, Table 5) (r = 0.79, 0.77
and 0.80 respectively).
The strongly significant intra-individual variance component in
CQ2 was due to 12 individuals, eight of whom repeatedly had
gametocytes and four who rarely presented with gametocytes.
Although the time since previous drug treatment was shorter in
these significant individuals, there was no difference between those
frequently carrying gametocytes and those rarely doing so (mean
32.4 days SEM 2.5 vs. 34.8 days SEM 2.02). There is thus no
indication that previous drug treatment is causing this intra-
individual effect. No obvious factor, such as age or sickle cell trait,
was shared by such individuals. Five of these individuals had
significant intra-individual estimates for PFA. Only one individual
had a significant intra-individual estimate in the CQ1 period and
was not significant in the CQ2 period.
Correlations between malaria phenotypes
There were no significant correlations in either individual
additive genetic or intra-individual effects between PFA and Pfgam
at any period where non-zero estimates were available.
Discussion
Here we have made an initial study of the heritability of two P.
falciparum malaria-related phenotypes in a single population over
time. The analyses divided the longitudinal study according to
drug treatment to examine the impact of the radical selection
pressure that would have been exerted on the parasite population
at each change in drug treatment. In addition, the change in
transmission intensity occurring over the 19 year enabled us to
assess its impact on the heritability of the malaria phenotypes. The
evolution of anti-malarial drug resistance and the force of infection
have been well studied in the population [36,37,40] and thus we
explored heritability in a single population undergoing well-
defined environmental changes.
Firstly, it was notable that for PFA, a phenotype known to be
influenced by human genetics, significant heritability was lost
following the change in drug treatment from quinine to
chloroquine and in subsequent drug periods. There was no
significant change in incidence rate, at least during the quinine
and chloroquine periods, no difference in the number of different
individuals presenting with clinical disease, or in the pedigree
structure (as estimated by the mean genetic relatedness). This
suggests that the implementation of the new drug in some way
interfered with the human genetic contribution to the outcome of
infection. In direct contrast, the intra-individual variance compo-
nent increased following the implementation of chloroquine.
Intra-individual variance encompasses effects specific to each
individual, classically including maternal effects and dominance
(non-additive) genetic effects [35,46]. There was no maternal effect
for the number of P. falciparum clinical episodes in our cohort at
any time period. The very high correlation of the individual
genetic and intra-individual estimates within each drug period
suggests that the two effects are highly confounded. This might be
a result of insufficient resolution of the relatedness matrix within
each drug period – i.e. either not enough relative-pairs were
present within each period and/or the IBD matrix was not
sufficiently resolved. This would lead to confounding between
shared environmental, additive and non-additive genetic effects
[47] and might explain the loss of heritability. However, given the
similarity in mean genetic relatedness of individuals in the quinine
(when the genetic effect was significant) and other periods, this
seems an insufficient explanation. One potential source of
variation would be local heterogeneity in individual exposure to
mosquitoes. The increase in the intra-individual variance compo-
nent as the transmission intensity decreased is consistent with
Table 4. Variance component analyses of the prevalence of
gametocytes in treated clinical episodes (Pfgam) according to
drug period.






genetic 0.423 0.317 1.340 0.181 20.197 1.044
Intra 0.196 0.272 0.720 0.236 0.040 156.760
House 0.000 . . . . .
residual 0.932 0.040 23.390 ,.0001 0.858 1.015
Chloroquine 1
genetic 0.164 0.195 0.840 0.401 20.218 0.545
Intra 0.380 0.218 1.750 0.041 0.159 1.814
House 0.000 . . . . .
residual 0.942 0.035 27.300 ,.0001 0.878 1.013
Chloroquine 2
genetic 0.000 . . . . .
Intra 0.530 0.119 4.440 ,.0001 0.356 0.870
House 0.127 0.090 1.410 0.079 0.045 1.050
residual 0.936 0.031 30.010 ,.0001 0.878 1.001
Fansidar
genetic 0.658 0.346 1.900 0.057 20.021 1.336
Intra 0.000 . . . . .
House 0.127 0.219 0.580 0.281 0.021 3389.110
residual 0.773 0.055 14.150 ,.0001 0.677 0.893
ACT
genetic 0.570 1.224 0.470 0.641 21.829 2.970
Intra 0.973 1.035 0.940 0.174 0.250 58.229
House 0.070 0.453 0.150 0.439 0.007 2.5E+65
residual 0.593 0.052 11.500 ,.0001 0.503 0.708
Genetic – additive genetic effect; Intra – Intra-individual effect; House – House
effect.
doi:10.1371/journal.pone.0026364.t004
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heterogeneity in mosquito biting. Although there was no evidence
for a significant impact of shared environment (house), heteroge-
neity in exposure may occur at a finer level of spatial resolution
and/or that reflecting individual behavioral differences ([48]
including commentary). One possible source of differential
exposure would come from bednet use. However, long-lasting
insecticidal-treated nets were not actively promoted until the
summer of 2008. Individuals showing extreme intra-individual
estimates shared no particular feature, whether it be age, sex or
time present in the study site. This argues against any particular
behavior or state of immunity contributing to the observed
increase in estimates. The intra-individual variance component
also includes environmental effects on an individual’s phenotype
that are constant across (or common to) repeated measures on that
individual [46]. It is notable that not only do individual estimates
correlate only with those from the subsequent drug period, but
also that the majority of the extreme values per individual
occurred in one drug period. One explanation for this concerns
the impact of the differing drug treatments on the parasite
population.
The most evident change in the parasite population during the
study was the development of resistance first to chloroquine and
then to Fansidar [40]. Treatment failure would result in the same
individual presenting more than once for the same infection, thus
artificially increasing that individual’s number of malaria episodes
and hence the estimated intra-individual effect. However, there
was no evidence for treatment failure biasing the number of
malaria episodes per person. The second effect of drug pressure
Figure 4. Proportion of variance in the prevalence of P. falciparum gametocytes during clinical P. falciparum episodes (Pfgam)
explained by additive genetic (solid line), intra-individual (dotted line, squares) and house (thin dotted line, triangles) effects.
doi:10.1371/journal.pone.0026364.g004
Table 5. Correlation of individual estimates of (i) the intra-individual and (ii) additive genetic effects underlying the variation in the
proportion of P. falciparum clinical episodes positive for gametocytes according to drug period.
Pfgam
(i) Intra Quinine CQ1 CQ2 Fansidar ACT
Quinine 0.23* 0.42*** - 0.33
CQ1 0.26** - 0.11
CQ2 - 0.34**
(ii) Genetic Quinine CQ1 CQ2 Fansidar ACT
Quinine 0.31** - 0.40* 0.27
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would be to radically reduce parasite diversity and select for a sub-
population of parasites. This process would not be instantaneous,
because the majority of the parasite population at any one time in
this cohort resides in untreated, asymptomatic infections. Thus,
the positive correlations of individual intra-individual and indeed
additive genetic estimates in consecutive drug periods might reflect
the slowly changing parasite population, implicitly suggesting the
existence of specific human-parasite interactions. Drug pressure
would result in a stochastic loss of particular parasite genotypes,
selection for drug resistant genotypes and potentially selection of
parasites more pathogenic for particular individuals. The changing
drug regimens would be expected to differentially select for
parasite genotypes at each instance, thus making it highly unlikely
that the same individuals would be continually susceptible. Whilst
an attractive hypothesis, a combination of immune state, behavior
and random focal transmission for specific periods of time could
generate the observed increase in the intra-individual effect. Our
study can not provide the immunological and parasite genetic data
that demonstrate changes in the parasite population that would
likely have clinical implications for a sub-set of individuals.
Moreover, given the complexity and uncertainty of the key
parasite antigens that are implicated in the development of clinical
immunity [49], such data might not be simple to interpret.
In contrast to the immeasurable effect of very fine scale spatial
heterogeneity in exposure to infection that will impact on PFA,
variability in gametocyte production in an infection will reflect the
influence of the host-parasite interaction. Both parasite and host
genetics can influence gametocyte production [27,50]. In this
study we found no additive genetic effect underlying the
proportion of clinical infections with gametocytes, confirming
our previous observations [27]. Interestingly, however, there was a
similar increase in the intra-individual effect to that observed for
PFA and the two phenotypes were not correlated. Moreover, as for
PFA, there was good correlation in estimates across only
consecutive periods. These comparable effects to PFA were
particularly notable during the period when transmission intensity
was stable. Subsequently, the decrease in intensity in the Fansidar
and ACT periods was accompanied by an even more significant
decrease in gametocyte prevalence, resulting in perilously small
sample sizes for reliable analysis.
Here, the period of drug treatment strongly influenced this
phenotype. Such an influence has been well documented following
treatment. Chloroquine increases gametocyte production [51] and
Fansidar has also been suggested to increase gametocyte
production [52] and/or longevity of gametocyte carriage in a
single infection with drug resistant parasites [53]. By contrast,
ACT has a gametocytocidal activity and reduces gametocyte
carriage [54]. Here, there were no indications that previous
treatment contributed to gametocyte presence at presentation,
thereby inflating the intra-individual effects in the chloroquine
periods. During the Fansidar period, a longer time since treatment
was associated with gametocyte presence. The variation in the
prevalence of gametocytes at presentation strongly suggests that
the parasite population altered according to drug period and the
correlated individual intra-individual estimates over successive
drug periods are similar to those seen for PFA. This would support
the hypothesis that changes in the parasite population diversity are
contributing to the observed phenotype.
Estimation of heritability in its broad sense in natural
populations is not possible and hence narrow sense heritability,
which estimates the additive genetic contribution, is calculated.
Actual values of heritability are specific for a study population at a
particular time and thus strict comparison is not informative,
although broad trends can be inferred. The size of heritability
provides an indication of the power to detect the effect of
individual genes when performing GWA studies. Here it is clear
that for several reasons, the choice of the study period for GWA
study analysis will affect the quality of the signal. The requirement
for large longitudinal data sets to generate sufficient power must
therefore be offset by the ever-increasing noise that accompanies
long-term data sets – more time means more variance [55].
The peculiarity of the variance component analyses in this study
was the replacement of an additive genetic component by an intra-
individual component over time. Classical components of the
intra-individual component, such as maternal effects, were not
found to be the root cause of this and spatial heterogeneity in
exposure seems an insufficient explanation, especially during the
quinine and chloroquine periods. Insufficient resolution and power
of the pedigree matrix may have led to confounding between
additive and non-additive genetic components, but again this
seems an inadequate explanation given the mean genetic
relatedness of the individuals implicated. Observed patterns of
individual estimates were consistent with there being specific host-
parasite interactions. Although relatives might be expected to
respond similarly to an identical parasite, this might not be
detectable as an additive genetic component. To what extent
changes in the parasite population can impact upon genetic studies
is important to understand, both on a practical level of study
sampling strategy and at a fundamental level to ask whether
candidate genes should be expected to have an effect under
whatever circumstances. In the hypothetical case of population
fixation of a protective gene, heritability will be zero. What will be
the expected heritability in a diverse human population if parasite
diversity approaches zero? Will certain genes only be protective
against a sub-set of parasites?
In this study we have found suggestive evidence that the parasite
population may impact upon estimates of heritability. Whereas a
review of theory and data have led to the suggestion that additive
genetic variance will represent the majority of genetic variance in
complex traits [56], this conclusion averages across populations
and may not therefore be the case within a single population [6],
especially in the case for infectious diseases. The complex,
polygenic basis to the human response to malaria parasite
infection may well include dominance/epistatic genetic effects
that are encompassed within the intra-individual effect. Evaluating
their role in host genotype by parasite genotype interactions in
model systems will surely be fruitful. In conclusion, prior genetic
analysis of carefully defined phenotypes, both spatially and
temporally delimited, must surely not only be a pre-requisite to
more detailed GWA studies, but also may be informative for the
potential importance of pathogen genetics and the occurrence of
host-pathogen interactions.
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